Innate Pharma S.A.
Innate Pharma S.A. (IPHA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · IPHA · as of Sep 30, 2025
Ownership Breakdown
9
Institutional Holders
$157,932
Total Inst. Value
▼ $20,749 vs Q2
93.90M
Shares Outstanding
freeFloat 70.19%
81,617
13F Shares Held
▼ 18,221 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
IPHA largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
MORGAN STANLEY biological products, (no diagnostic substances) | 53.6K | 6.27% | 6.27% | $103.38M | May 27, 2026 | ▲ 2.3K |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 20.0K | 2.35% | 2.35% | $39.08M | Nov 14, 2025 | ▼ 6.6K |
UBS GROUP AG biological products, (no diagnostic substances) | 4.8K | 0.56% | 0.56% | $9.26M | Nov 13, 2025 | ▼ 1.2K |
GAMMA INVESTING LLC biological products, (no diagnostic substances) | 2.3K | 0.27% | 0.27% | $4.40M | Oct 2, 2025 | ▼ 1.2K |
RHUMBLINE ADVISERS biological products, (no diagnostic substances) | 470 | 0.06% | 0.06% | $916,000 | Nov 6, 2025 | — held |
BARCLAYS PLC biological products, (no diagnostic substances) | 307 | 0.04% | 0.04% | $593,000 | Mar 31, 2026 | — held |
OPTIVER HOLDING B.V. biological products, (no diagnostic substances) | 101 | 0.01% | 0.01% | $197,000 | Nov 10, 2025 | — held |
PRINCIPAL SECURITIES, INC. biological products, (no diagnostic substances) | 45 | 0.01% | 0.01% | $87,000 | Nov 12, 2025 | — held |
FARTHER FINANCE ADVISORS, LLC biological products, (no diagnostic substances) | 10 | 0.00% | 0.00% | $19,000 | Oct 14, 2025 | NEW |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Nov 14, 2025 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
1
Increased
+2.3K shares1
New Positions
first time holders3
Decreased
−8.9K shares1
Sold Out
fully exitedNet shares change (top 50)
6.6K
+2.3K / −8.9K
Net new holders
-2
1 new / 1 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
IPHA insider trading · insider activity
Source: SEC Form 4
Recent Insider Transactions
Showing 10 most recent · Common Stock only
No recent insider transactions reported.
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Innate Pharma S.A. (IPHA) is primarily owned by institutional investors, who hold approximately 0.1% of total shares outstanding. Company insiders own approximately 29.81%, while retail and public investors account for the remaining 70.10%.
The largest institutional shareholder of Innate Pharma S.A. is MORGAN STANLEY, holding approximately 53,564 shares — equal to 6.27% of outstanding shares — as of September 30, 2025.
A total of 9 institutional investors currently hold IPHA stock, with a combined institutional value of approximately $157,932 as of the most recent 13F filing period.
Frequently asked questions
IPHA ownershipInnate Pharma S.A. (IPHA) is primarily owned by institutional investors, who hold approximately 0.1% of shares. The largest shareholder is MORGAN STANLEY with a 6.27% stake. Company insiders hold 29.81%. Data sourced from SEC Form 13F as of September 30, 2025.